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Summary
 
Objective
 
Here we use a novel ELISA that is specific for full-length
visfatin (PBEF/NAMPT), compare it with the existing C-terminal
based assay and use it to investigate associations of visfatin with
metabolic parameters.
 
Design, patients and measurements
 
We established the specificity
and effectiveness of the new ELISA and evaluated the associations
of full-length visfatin with clinical, anthropometric and metabolic
parameters in a cross-sectional study of 129 Thai subjects, consisting
of 50 outpatients with type 2 diabetes and 79 healthy volunteers.
 
Results
 
The new ELISA accurately recovered full-length recom-
binant visfatin and detected visfatin secreted by primary human and
rat adipocytes. We found serum full-length visfatin was significantly
higher in subjects with diabetes compared to their nondiabetic peers
(median 2·75 
 
vs
 
. 2·22 ng/ml, 
 
P
 
 = 0·0142). After adjustment for age,
gender and traditional metabolic risk factors, adjusted mean visfatin
remained significantly higher in the diabetes group (3·80 
 
vs
 
. 2·10 ng/ml,
 
P
 
 = 0·0021). On Spearman univariate correlation analysis, visfatin
was significantly associated with resistin (
 
r
 
 = 0·30, 
 
P
 
 = 0·0011), but
not with any other anthropometric or metabolic variables, including
adiponectin multimers. On multiple linear regression analysis, the
only covariates independently associated with visfatin were diabetes
(
 
t
 
 = 3·11, 
 
P
 
 = 0·0024) and log resistin (
 
t
 
 = 2·68, 
 
P
 
 = 0·0086).
 
Conclusions
 
Circulating visfatin is independently associated with
diabetes and resistin concentration, but is not related to adiponectin
multimers or other metabolic covariates. These data are suggestive
of a potential role of visfatin in subclinical inflammatory states.
(Received 25 January 2008; returned for revision 13 February 2008; 
 
finally revised 1 April 2008; accepted 2 April 2008)
 
Introduction
 
Visfatin [also known as Pre-B cell colony-enhancing factor (PBEF)
and nicotinamide phosphoribosyltransferase (NAMPT),
 
1,2
 
] is a novel
adipokine which was initially described as being highly expressed in
visceral fat and possessing insulin-mimetic bio-activity including
promotion of glucose disposal (note this work was subsequently
retracted) and more recently as a regulator of insulin secretion.
 
2,3
 
Given these findings, it was proposed as a potential factor in the
relationship between intra-abdominal obesity and type 2 diabetes.
 
4,5
 
Subsequent clinical studies, however, have yielded markedly conflict-
ing associations between visfatin and both diabetes and measures of
adiposity.
 
3,6–18
 
 Indeed, although circulating levels of visfatin were
initially correlated with visceral fat mass and with central obesity
 
6
 
 several
studies have noted (i) no difference in visfatin expression between
visceral and subcutaneous adipose tissue
 
12,13
 
 and (ii) no correlation
between circulating levels and measures of anthropometry and fat
mass (including multidetector computer tomography-determined
visceral and subcutaneous fat).
 
3,8,10–13
 
 As such, it has become
apparent that the physiologic relationships of this adipokine remain
unclear at this time.
 
19
 
Recently, a series of reports have noted associations between
visfatin and the acute-phase bio-markers C-reactive protein (CRP)
and IL-6, raising the possibility that this adipokine may play a role
in subclinical inflammation.
 
16,18,20,21
 
 In this context, the relationship
of visfatin to other adipokines that are known to be associated with
inflammation, such as resistin (pro-inflammatory) and adiponectin
(anti-inflammatory), emerges as a question of interest. To date,
however, there has been limited study of visfatin in relation to these
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adipokines. Indeed, the few such studies of total adiponectin have yielded
conflicting results and have not assessed the high-molecular-weight
(HMW), middle-molecular-weight (MMW) and low-molecular-
weight (LMW) multimeric forms of adiponectin.
 
6–8,10
 
 Thus, our
objective in the current analysis was to evaluate the correlations of
visfatin with a broad range of metabolic variables, including resistin
and adiponectin multimers, in a well-characterized clinical cohort.
 
22
 
To do this we first validated the specificity and accuracy of an assay
designed by Adipogen to measure full-length visfatin and compared
with the previously available C-terminal assay.
 
Methods
 
Subjects and measurements
 
A cross-sectional study was undertaken in 129 healthy volunteers
and outpatients attending a diabetes clinic of the Burapha University
Health Center in Thailand. The participants were (i) volunteers
from a diabetes mellitus outpatient clinic of the Burapha University
Health Center, Thailand, and (ii) healthy volunteers from the villages
around the health centre, representing the same catchment area from
which the diabetic subjects for this study were recruited. The subjects
with diabetes all had type 2 diabetes diagnosed by their treating
physician prior to their attendance at the diabetes clinic at which
they were recruited for the current study. Exclusion criteria included
current use of insulin and previous history of chronic disease, includ-
ing kidney, liver and inflammatory disorders. Participants with
diabetes on oral antidiabetic agents were receiving treatment with
either metformin or sulphonylureas, with no use of thiazolidinediones,
statins or antihypertensive medications. The study protocol was
approved by the ethics committee of Burapha University and all
participants provided written informed consent. On the day of
assessment, participants underwent physical examination consisting
of blood pressure measurement and a series of anthropometric
measurements, including weight, height, waist circumference, hip
circumference, mid-upper arm circumference and triceps skinfold
thickness measurement. Body mass index (BMI) and waist : hip ratio
were determined. Fasting venous blood samples were drawn for
biochemical studies.
 
Measurement of circulating and recombinant visfatin 
by ELISA
 
We used a new ELISA kit (AdipoGen, Seoul, Korea/ALPCO Diagnostics,
Salem, NH) designed to quantitatively measure visfatin in human
serum, plasma or cell culture supernatants. A monoclonal antibody
specific for human visfatin is precoated onto 96-well microplates and
bound standards or samples are captured by antihuman visfatin
polyclonal antibody which is then coupled to HRP-linked antirabbit
IgG for detection. This new ELISA exhibits increased sensitivity and
specificity for full-length visfatin. The sensitivity of this assay is
30 pg/ml; with a dynamic range of 0·0625–16 ng/ml; the mean intra-
assay variation (CV, 
 
n
 
 = 8 samples tested 10 time between 7·47 and
18·92 ng/ml), was 4·32%; the mean interassay variation (CV, 
 
n
 
 = 8
samples tested 10 time between 8·08 and 18·10 ng/ml) was 7·58%.
We also compared results obtained using this kit with an existing
commercially available ELISA (Phoenix Pharmaceuticals, Belmont,
CA) which is based upon detecting an epitope (amino acid residues
413–431) at the C-terminal domain of visfatin.
 
Differentiation of 3T3-L1 preadipocytes
 
3T3-L1 cells were grown and differentiated essentially as described
previously.
 
23
 
 In this case, 10 
 
μ
 
g/ml recombinant FLAG tagged human
visfatin or human insulin was added to 3T3-L1 cells that had been
treated with 1 
 
μ
 
m dexamethasone and 0·5 m
 
m
 
 IBMX for 2 days. After
a further 5 days, fat droplets were stained using oil-red O.
 
Isolation of human primary adipocytes and differentiation 
of primary human preadipocytes
 
Human preadipocytes were isolated from subcutaneous and omental
adipose tissue lipoaspirate waste material or omental tissue biopsies
as previously described.
 
24
 
 Primary human preadipocytes were
plated in preadipocyte media (DMEM/
 
F
 
12, 15 m
 
m
 
 HEPES,
10% FBS, Penicillin, Streptomycin, Amphotericin B) at a density
of 40 625 cells/cm
 
2
 
 in 6-well plates (390 813 cells per well in
3 ml/preadipocyte media) and allowed to attach the plate overnight
at 37 
 
°
 
C, 5% CO
 
2
 
. The following day, adipocyte differentiation was
induced by adding 3 ml of differentiation media [DMEM/Ham’s
F-10, 1 : 1, v/v; HEPES buffer (15 m
 
m
 
); fetal bovine serum (3%);
biotin (33 
 
μ
 
m), Pantothenate (17 
 
μ
 
m), human insulin (100 nm),
dexamethasone (0·5 
 
μ
 
m), PPAR agonist (1 
 
μ
 
m) and antibiotics] per
well and incubating without further feeding for 7 days. After the
differentiation period, 1·8 ml differentiation media was removed per
well and replaced with 2·4 ml of the same media lacking IBMX and
PPAR
 
γ
 
 agonist. Then the cells were allowed to mature without
further feeding for an additional 7 days. Conditioned media was
removed from each well and assessed for the presence of visfatin
(50 
 
μ
 
l in C-terminal and 100 
 
μ
 
l in full-length assays).
 
Induction of diabetes in rats using streptozotocin and 
isolation of primary rat adipocytes
 
Diabetes was induced in 6–8 week-old male Wistar rats with a single
i.p. injection of STZ (in 50 m
 
m
 
 citrate buffer, pH 4·5) at a dose of
100 mg/kg body weight. Blood glucose levels were routinely
measured with the OneTouch® Ultra® Meter glucometer (Lifescan,
Burnaby, BC, Canada) and a glucose tolerance test (2 g glucose/kg
body weight) was performed to confirm the induction of diabetes.
Adipocytes were isolated as previously described
 
25
 
 then the number of
adipocytes counted and the cell suspension diluted to 1 
 
×
 
 10
 
6
 
 cells/ml
with 10% FBS 
 
α
 
-MEM. Adipocytes were stabilized in a 25 cm
 
2
 
 cell
suspension flask for 3 h in humidified atmosphere (95% air and
5% CO
 
2
 
) at 37 
 
°
 
C. After stabilization, media was removed from
adipocytes and changed to serum free 
 
α
 
-MEM media and then used
to prepare conditioned media.
 
Clinical study – biochemical analyses
 
Circulating visfatin concentration was measured using the Adipogen/
ALPCO full-length visfatin ELISA. Total, HMW, MMW and LMW
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adiponectin levels were quantified by ELISA (ALPCO Diagnostics).
Resistin was measured by radioimmunoassay (RIA) from LINCO
Research (St. Charles, MO). Total cholesterol (TC) was determined
by a colorimetric method. Triglyceride (TG) levels were determined
by enzymatic colorimetric test with lipid clearing factor (GPO-PAP
method). Chylomicrons, very-low-density-lipoprotein cholesterol,
and low-density-lipoprotein (LDL) cholesterol were removed from
plasma by precipitation using phosphotungstic acid and magnesium
chloride. After centrifugation of the remaining plasma, high-density-
lipoprotein (HDL) cholesterol concentration in the supernatant was
measured in the same way as TC. LDL was calculated according to
the formula LDL = TC – HDL – (TG/5) mg/dl. Fasting plasma
glucose was measured by the enzymatic colorimetric method of
Ware and Marbach. Fasting insulin was measured by RIA from
LINCO Research. The Homeostasis Model of Assessment of insulin
resistance (HOMA-IR)
 
26
 
 was calculated as fasting insulin (
 
μ
 
U/ml)
multiplied by fasting glucose (mmol/l) divided by 22·5. The HOMA
of 
 
β
 
-cell function (HOMA-B)
 
26
 
 was calculated as (20 
 
× 
 
fasting
insulin)/(fasting glucose – 3·5).
 
Statistical analysis
 
All statistical analyses for clinical studies were conducted using the
Statistical Analysis System (
 
sas
 
, Version 9·1, SAS Institute, Cary,
NC). In Table 2, continuous variables are presented as mean followed
by SD and categorical variables are presented as percentages. The
distributions of ALT, TG, fasting glucose, HOMA-IR, HOMA-B,
resistin, visfatin and total, HMW, MMW and LMW adiponectin
were skewed and thus medians and interquartile ranges are presented
for these variables in Table 2. The natural logarithmic transforma-
tions of these skewed variables were used in subsequent multivariate
analyses, with back-transformed values presented where applicable.
In Table 2, differences between the diabetic and nondiabetic groups
were determined by 
 
t
 
-test and 
 
χ
 
2
 
-test for continuous and categorical
variables, respectively. Analysis of covariance (
 
ancova
 
) was used to
assess differences in mean visfatin between study participants with
and without diabetes, after adjustment for age, gender, BMI, waist
circumference, systolic blood pressure, LDL, HDL, TGs, fasting
glucose and HOMA-IR and diabetes. Spearman correlation analysis
was performed to assess the univariate associations of visfatin
with anthropometric and metabolic variables, with subsequent
adjustment for age, gender and diabetes (Table 3). Multiple linear
regression analysis was used to determine factors independently
associated with dependent variable log visfatin (Table 4). Covariates
in this model were demographic factors (age, gender), traditional
metabolic/vascular risk factors (BMI, waist circumference, systolic
blood pressure, LDL, TGs, HOMA-IR, diabetes) and variables found
to be significantly associated with visfatin on univariate analysis
(resistin). Finally, 
 
ancova
 
 was used to assess differences in mean
visfatin between study participants stratified by tertiles of resistin,
after adjustment for age, gender, diabetes, HOMA-IR and three
distinct elements of adiposity (BMI, waist circumference, triceps
skinfold). In all other cases, data are expressed as means ± SEM and
statistical analysis was undertaken using paired Student’s 
 
t
 
-test.
 
Results
 
We first established the specificity and sensitivity of the new full-
length visfatin assay. Using Western blotting, we confirmed that the
antibodies used in this assay were highly specific for recombinant
human and rodent visfatin (data not shown). Unlike the previous
commercially available assay which uses a C-terminal fragment
(413–431) of visfatin as standard, this new assay uses recombinant
FLAG-tagged full-length visfatin (1–491) as standard and indeed did
not detect the C-terminal peptide as efficiently (data not shown).
Fig. 1a shows that this assay accurately recovers serial dilutions of
recombinant FLAG-tagged protein. In contrast, Table 1 shows the
limited specificity of the C-terminal ELISA for various forms of
recombinant visfatin. In this analysis, three visfatin recombinant
proteins were analysed with the C-terminal visfatin ELISA: C-terminal
peptide (413–431), FLAG-tagged full-length human visfatin and
His-tagged full-length human visfatin. C-terminus visfatin concen-
trations were recognized, but were significantly decreased and did
not vary as would be expected with concentrations added. FLAG-
and His-tagged full-length visfatin recombinant proteins were 100-
fold decreased in terms of the actual values detected, albeit in parallel
Visfatin standards 
Concentration (ng/ml)
Recovered 
value (ng/ml)
C-term visfatin peptide (human visfatin 
amino acids 413–431)
500 197·89 ± 20·07
250 194·25 ± 23·71
125 152·90 ± 17·64
62·5 190·35 ± 12·53
FLAG-visfatin peptide (full-length human 
visfatin (1–491) with FLAG at N-terminus)
500 6·21 ± 0·57
250 4·27 ± 0·10
125 2·44 ± 0·31
62·5 0·77 ± 0·14
His-visfatin peptide (full-length human 
visfatin 1–491) with 6x His at N-terminus) 
500 4·56 ± 0·44
250 2·40 ± 0·54
125 0·79 ± 0·06
62·5 0·49 ± 0·14
Table 1. Ability of C-terminal visfatin assay to 
detect full-length and C-terminal fragments of 
the protein. Serial dilutions of recombinant 
proteins (500–62·5 ng/ml) were analyzed and 
recovered values shown are mean ± SD of 
duplicate samples from two independent 
experiments
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to changes in concentration of visfatin added. Indeed, as shown in
(Fig. 1b), the correlation between the full-length and C-terminal assays
is surprisingly modest for two assays that are supposed to measure
the same analyte (nonparametric Spearman correlation coefficient
 
r
 
 = 0·4121 and 
 
P
 
 = 0·0091). Finally, the new full-length visfatin assay
was tested for cross reactivity with a variety of targets and showed
100% cross reactivity with both human and rat visfatin and no cross
reactivity with human adiponectin, resistin, RELM-
 
β
 
, leptin, GPX3,
ANGPTL4, FABP4, AGF and PAI-1 (data not shown).
We have demonstrated that the recombinant FLAG-tagged full-
length human visfatin used as standard in the new assay exhibits
potent biological activity. This was confirmed via stimulation of
differentiation of 3T3-L1 fibroblasts to adipocytes with insulin used
as comparison for positive control (data not shown). As visfatin
mRNA has previously been demonstrated in adipocytes
 
27,28
 
 here we
examined whether primary human or rat adipocytes secreted the
full-length protein. Figure 1c shows that visfatin is indeed secreted
by human primary adipocytes, with a tendency towards higher levels
in omental-derived adipocytes compared to adipocytes obtained
from the subcutaneous depot. We also observed a time-dependent
secretion of visfatin into culture medium by rat adipocytes, higher
at 24 h than at 2 h (Fig. 1d). Comparing adipocytes from both wild-
type and streptozotocin-induced diabetic rats, a model of pancreatic
 
β
 
-cell destruction and hypoinsulinaemia, we also demonstrated that
visfatin is secreted at reduced levels by adipocytes from streptozotocin-
induced diabetic rats (Fig. 1d).
We next examined the associations of visfatin with a broad range
of metabolic parameters in a clinical study of 129 subjects using
the new full-length assay. Table 2 shows demographic, clinical and
metabolic characteristics of the 129 study participants stratified by
the presence (
 
n
 
 = 50) or absence (
 
n
 
 = 79) of diabetes. Subjects with
diabetes were older than their nondiabetic peers. As expected, the
diabetic participants exhibited greater adiposity (BMI, waist
circumference, waist : hip ratio, triceps skinfold, mid-upper arm
circumference), higher fasting glucose, greater insulin resistance
(HOMA-IR) and poorer 
 
β
 
-cell function (HOMA-B). In addition,
the diabetic group had higher serum creatinine, ALT, TGs, LDL
cholesterol, TC and resistin levels Importantly, serum visfatin was
Fig. 1 Characteristics and validation of full-length visfatin ELISA and comparison with C-terminal assay. (a) Shows a standard curve of serial dilutions (0·0625–
16 ng/ml) of recombinant human FLAG-tagged visfatin using this new assay. (b) Shows that upon analysis of human serum there was a modest correlation 
between the two assays (r = 0·4121, P = 0·0091), indicating that the new full-length visfatin assay only explains 17·56% of the variance in the C-terminal assay. 
Solid line indicates a regression line with the equation: [C-terminal visfatin] = 1·291 [full-length visfatin] + 46·65 ng/ml. The dotted lines indicate the 95% 
confidence interval for the regression line. This figure also demonstrates that visfatin is secreted by both human (c) and rat (d) primary adipocytes. In the 
human studies, cells from both omental (OM) and subcutaneous (SQ) depots were studied with higher visfatin levels being apparent in the omental-derived 
adipocytes. For all analyses after being drawn from the subjects, blood was allowed to clot for 15–30 mins, then centrifuged for 10 mins at 1500 g. Supernatant 
was frozen at –80 °C until assays were performed. Visfatin was measured in fresh (never defrosted) human serum that had been stored at –80 °C. Measurements 
were performed in each assay using the same sample on the same day. Adipocytes from both wild-type (wt) and streptozotocin-induced diabetic (stz) rats 
were studied and visfatin was secreted in a time-dependent manner and at reduced levels by adipocytes from diabetic animals. All values are mean ± SEM of 
n > 3 and * signifies P < 0·05 vs. wt 2 h and ** P < 0·05 vs. wt 24 h.
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significantly higher in participants with diabetes compared to their
nondiabetic peers (median 2·75 
 
vs.
 
 2·22 ng/ml, 
 
P
 
 = 0·0142). After
adjustment for age, gender and traditional metabolic risk factors
(BMI, waist circumference, systolic blood pressure, LDL, HDL, TGs,
fasting glucose and HOMA-IR), adjusted mean visfatin remained
significantly higher in the diabetes group (3·80 
 
vs.
 
 2·10 ng/ml,
 
P
 
 = 0·0021).
On Spearman univariate correlation analysis (Table 3), the only
metabolic covariate with which visfatin was significantly associated
was resistin (
 
r
 
 =
 
 
 
0·30, 
 
P
 
 = 0·0011). This relationship remained
significant after further adjustment for age, gender and diabetes. In
contrast, visfatin exhibited no significant univariate correlations with
any anthropometric measurements, creatinine, ALT, lipid measures,
fasting glucose, insulin resistance (HOMA-IR), 
 
β
 
-cell function
(HOMA-B), total adiponectin or individual adiponectin multimeric
forms. Furthermore, whereas a multiple linear regression model
consisting of age, gender, BMI, waist circumference, systolic blood
pressure, LDL, TGs, HOMA-IR, diabetes and resistin explained 19·3%
of the variance in dependent variable log visfatin (Table 4), the only
covariates independently associated with visfatin were diabetes
(
 
t
 
 = 3·11, 
 
P
 
 = 0·0024) and log resistin (
 
t
 
 = 2·68, 
 
P
 
 = 0·0086).
Having identified an association between the adipokines visfatin
and resistin, we sought to further evaluate this relationship. Indeed,
after adjustment for age, gender, diabetes, insulin resistance (HOMA-
IR) and three distinct elements of adiposity (BMI, waist circumference,
triceps skinfold), mean visfatin was lowest in subjects in the lowest
tertile of resistin concentration (2·27 ng/ml) and rose progressively
over the middle (2·74 ng/ml) and highest tertiles (3·18 ng/ml),
respectively (trend 
 
P
 
 = 0·0392), consistent with an independent
association between visfatin and resistin.
 
Discussion
 
In this report, we have used a new ELISA which specifically and
accurately measures full-length visfatin to evaluate the clinical and
metabolic correlates of circulating visfatin. The data reported herein
Table 2. Demographic, clinical and metabolic characteristics of study participants, stratified by presence or absence of diabetes
No diabetes (n = 79) Diabetes (n = 50) P
Demographics
Age (year) 52·9 (10·7) 57·5 (8·7)  0·0122
Gender (M/F) 16%/84% 12%/88%  0·4883
Anthropometry
BMI (kg/m2) 24·9 (4·0) 26·6 (4·9)  0·0331
Waist (cm) 83·2 (9·4) 93·0 (9·3) < 0·0001
Waist : hip ratio 0·87 (0·04) 0·93 (0·05) < 0·0001
Triceps skinfold 28·3 (8·8) 24·7 (5·9)  0·0175
Mid-upper arm circumference 29·8 (3·2) 31·6 (3·8)  0·0097
Liver/renal
Creatinine (mg/dl) 0·82 (0·21) 1·05 (0·38) < 0·0001
ALT 22 (16–30) 26 (19–36)  0·0478
Traditional risk factors
Systolic BP (mmHg) 129·1 (25·0) 137·0 (16·8)  0·0661
Diastolic BP (mmHg) 80·0 (14·2) 84·7 (10·6)  0·0574
Total cholesterol (mg/dl) 220·5 (48·2) 263·6 (78·5)  0·0002
LDL (mg/dl) 149·2 (45·7) 184·0 (78·9)  0·0033
HDL (mg/dl) 47·1 (12·3) 44·3 (10·1)  0·1793
Triglycerides (mg/dl) 116·0 (74·0–169·0) 169·0 (107·0–226·0)  0·0004
Fasting glucose (mmol/l) 4·6 (4·2–5·4) 6·7 (5·6–8·4) < 0·0001
HOMA-IR 3·0 (2·1–4·1) 5·8 (3·6–7·4) < 0·0001
HOMA-B 248·3 (138·7–420·3) 103·1 (64·9–201·6)  0·0002
Non-traditional risk factors
Total adiponectin (μg/ml) 6·01 (4·77–8·33) 5·38 (4·40–6·23)  0·1326
HMW adiponectin (μg/ml) 3·91 (2·60–5·49) 3·36 (2·45–3·97)  0·1697
MMW adiponectin (μg/ml) 1·15 (0·74–1·53) 1·25 (0·78–1·59)  0·5127
LMW adiponectin (μg/ml) 1·18 (0·84–1·81) 1·01 (0·69–1·45)  0·1735
Resistin 1·89 (1·15–2·95) 2·88 (1·85–4·60)  0·0187
Visfatin (ng/ml) 2·22 (1·36–4·08) 2·75 (1·83–4·61)  0·0142
Data presented as mean followed by SD in parentheses except for (i) gender (presented as percentages) and (ii) ALT, triglycerides, fasting glucose, 
HOMA-IR, HOMA-B, adiponectin (total, HMW, MMW, LMW), resistin and visfatin (presented as median followed by interquartile range in parentheses).
P-values refer to differences between groups as determined by t-test and χ2 test for continuous and categorical variables, respectively.
Note adiponectin was measured in 96 subjects (41 with diabetes).
Bold value implies P < 0·05.
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support earlier observations of an independent relationship between
visfatin and diabetes. However, there was no correlation of visfatin
with other metabolic covariates, including anthropometric measure-
ments, lipid measures, fasting glucose, insulin resistance and β-cell
function. Instead, full-length visfatin is found to be independently
associated with circulating resistin concentration but not related to
adiponectin or its multimers. As such, the biology of visfatin in rela-
tion to other adipokines and inflammatory proteins emerges as an
area that warrants further study.
It must be noted that the existing literature has produced many
paradoxical observations regarding the clinical correlates of circu-
lating visfatin.3,6–18 It is now becoming apparent that at least part of
the reason for the discrepancies reported lies in the assays used to
measure visfatin. To date, the majority of clinical studies have utilized
a commercial competitive assay that recognizes the carboxy-terminal
of the visfatin protein. In these studies, the reported concentrations
of circulating visfatin have shown marked variability, ranging from
about 1–3 ng/ml in some studies10,29 to between 14 and 50 ng/ml in
most reports.19 The physiologic associations reported have also been
inconsistent. Indeed, although circulating levels of visfatin were
initially thought to be correlated with visceral fat mass and with
central obesity6,30 several studies have noted (i) no difference in
visfatin expression between visceral and subcutaneous adipose
tissue12,13 and (ii) no correlation between circulating levels and
measures of anthropometry and fat mass (including multidetector
computer tomography-determined visceral and subcutaneous
fat).3,8,10–13 The fact that the physiologically relevant full-length
visfatin was not detected by the carboxy-terminal assay has been
proposed as a potential explanation for these inconsistent results.
Indeed, our data suggest that the C-terminal assay measures recom-
binant full-length human visfatin around 100–200-fold lower than
the true values. This data supports recent suggestions that this
assay is compromised by interference with a nonspecific HMW
compound.28 Thus, we believe that it is important to document that
Table 3. Spearman univariate correlations of visfatin: (i) unadjusted (ii) adjusted for age and gender, and (iii) adjusted for age, gender and diabetes
Unadjusted
Adjusted for age 
and gender
Adjusted for age, 
gender and diabetes
r P r P r P
Age –0·13 0·1410
BMI 0·14 0·1047 0·15 0·1198 0·11 0·2516
Waist circumference 0·15 0·1212 0·18 0·0590 0·06 0·5359
Triceps skinfold –0·11 0·2511 –0·13 0·2002 –0·08 0·4271
Mid-upper arm circumference 0·07 0·4767 0·05 0·5805 –0·02 0·8075
Creatinine 0 0·9579 0·03 0·7620 –0·11 0·2749
ALT 0·15 0·0898 0·17 0·0844 0·12 0·2268
Systolic BP 0·05 0·6291 0·12 0·2284 0·07 0·4975
Diastolic BP 0·02 0·8132 0·02 0·8399 –0·05 0·5856
LDL –0·01 0·9328 0 0·9606 –0·07 0·4821
HDL –0·10 0·2632 –0·12 0·2396 –0·08 0·4405
Triglycerides –0·03 0·7480 0 0·9636 –0·11 0·2654
Fasting glucose 0·03 0·7328 0·07 0·4746 –0·11 0·2885
HOMA-IR 0·03 0·7622 0·02 0·8782 –0·13 0·1919
HOMA-B –0·02 0·8690 –0·08 0·4153 0·05 0·6333
Total adiponectin –0·13 0·2040 –0·12 0·2524 –0·08 0·4331
HMW adiponectin –0·16 0·1238 –0·14 0·1710 –0·10 0·3200
HMW : total adiponectin –0·07 0·4761 –0·05 0·6303 –0·02 0·8431
MMW adiponectin –0·07 0·5088 –0·07 0·5156 –0·07 0·4774
MMW : total adiponectin 0·00 0·9851 –0·02 0·8651 –0·05 0·6508
LMW adiponectin 0·01 0·9286 0 0·9799 0·02 0·8687
LMW : total adiponectin 0·09 0·3992 0·07 0·4907 0·07 0·5035
Resistin 0·30 0·0011 0·28 0·0041 0·21 0·0287
Bold values imply P < 0·05.
Table 4. Multiple linear regression analysis of dependent variable log visfatin
β-estimate t-value P
Age –0·0073 –0·81 0·4192
Gender –0·1912 –0·69 0·4913
Body mass index 0·0111 0·47 0·6377
Waist circumference –0·0043 –0·39 0·6984
Systolic blood pressure 0·0013 0·37 0·7157
LDL –0·0023 –1·89 0·0618
Log triglycerides –0·1046 –0·70 0·4838
Log HOMA-IR –0·1571 –1·51 0·1337
Diabetes 0·5362 3·11 0·0024
Log resistin 0·2917 2·68 0·0086
Model r2 = 19·3%.
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the newly developed assay used in our study accurately and specifi-
cally detects circulating human full-length visfatin and this in itself
may help to clarify the physiological role of this protein.
Our current findings confirm that type 2 diabetes is associated with
increased circulating visfatin, as has been reported in most3,6–9 but
not all10,11 previous studies. Furthermore, again in agreement with
the majority of previous studies3,12,14 there was no association between
visfatin and insulin sensitivity/resistance. In contrast, although
increased serum visfatin has been linked to β-cell dysfunction in
one study3 no correlation was noted with HOMA-B in the current
analysis. This discrepancy may be due to the limitations of HOMA-B
as a marker of β-cell function and hence further study of full-length
visfatin with more sensitive β-cell measures is needed. Overall, our
findings suggest that full-length visfatin is associated with type 2
diabetes but not with other metabolic variables, including anthro-
pometric measurements, lipid measures, fasting glucose and insulin
resistance.
There has been a great deal of controversy recently regarding the
validity of initial suggestions that visfatin was an insulin-mimetic
hormone.1,2,5,28,31 Indeed, it has been suggested that the cytokine-like
function of PBEF and the insulin-mimetic function of visfatin could
be explained by the NAD biosynthetic activity of this protein as
NAMPT.1,2 It has therefore been suggested that promotion of systemic
NAD biosynthesis represents one mechanism via which the body
might attempt to maintain β-cell function in obesity and type 2
diabetes. Indeed, circulating PBEF/NAMPT/visfatin level was recently
proposed as an indicator of beneficial lipid profile.32 This idea is con-
sistent with our data which demonstrated an elevation in circulating
levels of this protein in individuals with type 2 diabetes compared
to their nondiabetic peers, even after adjustment for age, gender and
traditional metabolic risk factors. Furthermore, recent published
work has strengthened the link between visfatin and inflammatory
signal modulation.18,21,33
A novel finding in this report is the independent association
between circulating visfatin and resistin. While the role of resistin in
human obesity, insulin resistance, and type 2 diabetes remains
controversial34 increased resistin has been proposed as a mediator
of inflammation in humans.34,35 Taken together with the emerging
recognition of obesity as a state of low-grade inflammation associated
with increased macrophage infiltration of adipose compartments,36,37
the demonstration that macrophages are the predominant source of
both resistin and visfatin in human visceral adipose tissue raised the
possibility that both of these adipokines may be pro-inflammatory
factors in obese individuals.38 Indeed, visfatin has been characterized
as an inflammatory cytokine in neutrophils39 and as pro-inflammatory
in atherosclerosis.40 In addition, visfatin has been positively associated
with CRP and IL-6 in patients with chronic kidney disease20 and a
visfatin promoter polymorphism has been linked to increased plasma
levels of CRP and fibrinogen41 consistent with an inflammatory
role of the protein.42 While an earlier study found no correlation
between serum visfatin and resistin,6 Li et al. recently reported a
positive univariate association that did not persist on multivariate
adjustment.43 The current study thus extends this literature by
demonstrating an independent association between full-length
visfatin and resistin. Further study of full-length visfatin in relation
to inflammatory markers is warranted at this time.
Previous studies have yielded conflicting results regarding the
relationship between visfatin and adiponectin. While Chen et al.
reported an inverse association6 subsequent studies have found no
correlation between visfatin and total adiponectin.7,8,10 It should be
noted that adiponectin circulates as LMW, MMW and HMW
multimeric forms,44 which are believed to mediate distinct aspects
of the pleiotropic bio-activity of the protein.45,46 The HMW isoform
has been linked to insulin-sensitizing and vascular-protective effects47,48
while LMW adiponectin has been correlated with anti-inflammatory
activity.49 We thus speculated that differences in multimer distribution
may underlie the conflicting associations reported to date between
total adiponectin and visfatin. While the current analysis extends the
literature by addressing the impact of adiponectin multimeric forms
in this context, no correlation was detected between full-length vis-
fatin and total, HMW, MMW and LMW adiponectin, respectively.
Certain limitations should be noted in this study. Firstly, the cross-
sectional nature of the protocol precludes commentary on causality
in the relationships under study. Secondly, the study population was
modest in size (n = 129) and consisted of a single ethnic group (Thai).
Thirdly, subjects with diabetes were assessed without stopping their
oral antidiabetic agents, which theoretically could affect the relation-
ships under study. It should be noted, however, that metformin and
sulphonylureas (the only agents used by participants) have not been
associated with changes in visfatin levels in earlier reports.3,12
In summary, circulating full-length visfatin measured by this
newly developed assay is independently associated with diabetes but
not with other metabolic covariates, including anthropometric
measurements, lipid profile, fasting glucose, insulin resistance and
β-cell function. Instead, visfatin is independently associated with cir-
culating resistin concentration, while not related to total adiponectin
or its individual multimeric forms. These data are in keeping with
the emerging consensus of opinion and suggest that further study
of the relationships of full-length visfatin with other adipokines and
inflammatory proteins may help to elucidate the complex physiology
of this protein.
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